The short version of somatotroph fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-02-22. Anything still debated is marked as such rather than presented as settled.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Amino acid length | 44 residues | Matches the native peptide backbone |
| Molecular weight | Approximately 5135 Da | Calculated from the peptide sequence |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
| Primary studied use | Visceral fat reduction | Investigated in HIV-associated lipodystrophy |
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
In biochemistry, two biopolymers are antiparallel if they run parallel to each other but with opposite directionality (alignments). An example is the two complementary strands of a DNA double helix, which run in opposite directions alongside each other. Nucleic acid molecules have a phosphoryl (5') end and a hydroxyl (3') end. This notation follows from organic chemistry nomenclature, and can be used to define the movement of enzymes such as DNA polymerases relative to the DNA strand in a non-arbitrary manner.
Naturally occurring gadolinium (64Gd) is composed of six stable isotopes, 154Gd, 155Gd, 156Gd, 157Gd, 158Gd and 160Gd, and one long-lived radioisotope, 152Gd, with 158Gd being the most abundant (24.84% natural abundance). The predicted double beta decay of 160Gd has not been observed. In all, 32 radioisotopes of gadolinium have been characterized, with the three most stable being alpha emitters: 152Gd (naturally occurring) with a half-life of 1.08×1014 years, 150Gd with a half-life of 1.79×106 years, and 148Gd (theoretically not beta-stable) with a half-life of 86.9 years. All of the remaining radioactive isotopes have half-lives less than a year, the majority of these having half-lives less than two minutes. There are also 16 metastable isomers, with the most stable being 143mGd (t1/2 = 110 seconds), 145mGd (t1/2 = 85 seconds) and 141mGd (t1/2 = 24.5 seconds). The isotopes with atomic masses lower than the most abundant stable isotope, 158Gd, primarily decay by electron capture to isotopes of europium. For higher atomic masses, the primary decay mode is beta decay to isotopes of terbium.
The Welsh Conservatives are absent from a Senedd debate concerning their former leader, Andrew RT Davies, but reject allegations they are boycotting the chamber's disciplinary process. 6 February – Chris McEleny is suspended as general secretary of the Alba Party following allegations of gross misconduct. 7 February – Reform UK chairman Zia Yusuf tells the BBC's Political Thinking podcast that history will judge Boris Johnson as one of the most damaging prime ministers in British history. 8 February – Health Minister Andrew Gwynne is sacked by the prime minister after the Mail on Sunday reported he sent a string of abusive and insulting WhatsApp about constituents and colleagues. Gwynne apologises for what he describes as the "badly misjudged" messages. 9 February – Conservative shadow minister Alex Burghart tells the BBC's Sunday with Laura Kuenssberg there is "not a conversation to be had" about suggestions of an electoral pact with Reform UK. Oliver Ryan, MP for Burnley, becomes the second MP to apologise for inappropriate comments made in a WhatsApp chat. 10 February – Peter Mandelson begins his tenure as United Kingdom ambassador to the United States, and tells the BBC the UK must respect President Donald Trump's "strong and clear mandate for change". Oliver Ryan is suspended from the Parliamentary Labour Party over his membership of a WhatsApp group in which offensive messages were exchanged. King Charles III gives the prime minister and deputy prime minister a tour of his environmentally friendly, sustainable housing project at Nansledan in Cornwall.
Sources: en.wikipedia.org
== See also == Lysergamide § Related compounds Substituted isotryptamine List of investigational hallucinogens and entactogens List of miscellaneous 5-HT2A receptor agonists Non-hallucinogenic 5-HT2A receptor agonist BOL-148 (2-bromo-LSD) and SPT-348 SDZ SER-082 DLX-0002700 LEK-8829 LSD-Quinoline
== External links == GeneReviews/NCBI/NIH/UW entry on Familial Exudative Vitreoretinopathy, Autosomal Dominant This article incorporates text from the United States National Library of Medicine, which is in the public domain.
Ubayd Allah's father prepared him to succeed him as governor, and indeed, after Ziyad's death in 672/673, Ubayd Allah became governor of Khurasan. A year or two later, he was also appointed to the governorship of Basra. According to historian Hugh N. Kennedy, Ubayd Allah was "more hasty and given to the use of force than his father, but a man whose devotion to the Umayyad cause could not have been doubted". In 674 he crossed the Amu Darya and defeated the forces of the ruler of Bukhara in the first known invasion of the city by Muslim Arabs. After he was appointed governor of Basra soon afterwards, he also took several thousand Bukharan captives with him as slaves. Out of those slaves the Bukhariya military unit was formed. From at least 674 and 675, Ubayd Allah had coins struck in his name in Khurasan and Basra, respectively. They were based on Sasanian coinage and written in Pahlavi script. The mints were located in Basra, Darabjird, Maysan, Narmashir, Jayy and, to a lesser extent, Kufa. The latter was attached to Ubayd Allah's governorship in 679/680, giving him full control of Iraq.
Sources: en.wikipedia.org
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.
The synthetic peptide incorporates modifications that slow enzymatic breakdown in circulation. Native growth hormone-releasing hormone is short-lived, whereas the analog is designed for greater stability. The core amino acid backbone is largely retained.
The main studied application is reduction of excess visceral abdominal fat in HIV-associated lipodystrophy. Research has measured fat changes through imaging. Findings concern fat distribution rather than overall body weight.
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.